SMMT Shares Updated Ivonescimab Survival Data From NSCLC Study

Summit announced updated overall survival (HARMONi) data and expanded late-stage development by partnering with Arcus to test ivonescimab in kidney cancer. While no quantitative figures were provided, the combined survival-data update and new trial collaboration are incremental positives for clinical momentum. The news is likely supportive for sentiment around the program, but may not be market-wide without detailed efficacy metrics or near-term readouts.

Analysis

Summit announced updated overall survival (HARMONi) data and expanded late-stage development by partnering with Arcus to test ivonescimab in kidney cancer. While no quantitative figures were provided, the combined survival-data update and new trial collaboration are incremental positives for clinical momentum. The news is likely supportive for sentiment around the program, but may not be market-wide without detailed efficacy metrics or near-term readouts.